Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $1.67M fell 5.3% year over year, behind the +38.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 68.6% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +29.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.67M-68.6% QoQ
- Last fiscal yearDec 2025
- $10.49M+29.3% YoY
- LTMMar 2026
- $10.4M+38.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.3% | -100.0% | -94.7 pp |
| 1 year | +29.3% | -100.0% | -129.3 pp |
| 3-year CAGR | +6.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 10.49M USD
- Year-over-year change
- +29.3%
- 4-year CAGR
- +19.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.49M | +29.3% |
| FY2024 | 2024-12-31 | 8.11M | -7.3% |
| FY2023 | 2023-12-31 | 8.76M | +2.0% |
| FY2022 | 2022-12-31 | 8.59M | +64.9% |
| FY2021 | 2021-12-31 | 5.21M | — |
Selling, General & Admin vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 selling, general & admin of $10.4M is the highest of the 2 companies compared; the peer median is $7.25M.
- Its year-over-year change of +38.2% is the highest of 2, against a peer median of +10.7%.
- Over three fiscal years its annual growth of +6.9% compares with a peer median of +19.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.4M | +38.2% | +6.9% | — | |
| LTM Jun 2026 | $7.25M | +10.7% | +19.0% | — | |
| Peer median (excluding INDP) | $7.25M | +10.7% | +19.0% | — | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
| Selling, General & Admin | 5.21M | 8.59M | 8.76M | 8.11M | 10.49M |
| Operating Expenses | 7.73M | 14.91M | 16.38M | 15.37M | 19.83M |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| EBITDA | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.73M) | (14.91M) | (16.38M) | (15.37M) | (19.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.72K | 588.11K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17.72K | 588.11K | 955K | 343.72K | (1.02M) |
| Income Before Tax | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| EPS (Diluted) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| Weighted Avg Shares | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
| Weighted Avg Shares (Diluted) | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.